BCTX - Briacell Therapeutics falls ahead of presentation at medical event

The shares of clinical-stage biotech, Briacell Therapeutics (NASDAQ:BCTX), have recorded the worst intraday decline in more than a year on Tuesday as the Canadian company awaits its presentation at the ongoing American Association for Cancer Research (AACR) Annual Meeting. The exhibit titled “Toward a personalized off-the-shelf cellular immunotherapy for cancer” is scheduled for Tuesday from 2:30 to 6:00 p.m. ET Briacell (BCTX) announced in February with an update on its buyback program. BriaCell (BCTX) is advancing its lead candidate BRIA-IMT in early-stage trials for advanced breast cancer in combination with immune checkpoint inhibitors. A presentation on Phase I/II data for BRIA-IMT conducted at San Antonio Breast Cancer Symposium failed to impress Briacell (BCTX) investors last year.

For further details see:

Briacell Therapeutics falls ahead of presentation at medical event